Magnitude Biosciences
Magnitude provides lab study services using C. elegans organisms to test compounds for clients.
01What it doesMagnitude provides lab study services using C. elegans organisms to test compounds for clients.Source-grounded · automated review · Explore ↗
Checked 2026-09-15 · Review due 2026-09-22
Read supporting source ↗Our customised C. elegans studies…
02Who is involvedEvidence still neededOpen review status ↗
No supplied document names investors, previous-round investors, arrangers, lenders, or any financing-role participants for this record.
03What happenedEvidence still neededOpen review status ↗
No supplied document establishes a financing event, round, amount, currency, valuation, or announced transaction date. The target date 2026-09-15 is not supported by the document.
04Why it mattersEvidence still neededOpen review status ↗
Supported as a modest relevance interpretation: the document says Magnitude’s studies helped clients efficiently prioritise key compounds and describes use in early-stage drug development. No stronger financing or outcome implication is supported.
Magnitude Biosciences · Financing Record
Explore source-linked visual explanations for Magnitude Biosciences. Unsupported claims are withheld while source review continues.
Record 12315 · Recorded date: 2026-09-15
Explore company records →